Ventyx Biosciences Inc. (VTYX)
NASDAQ: VTYX
· Real-Time Price · USD
1.20
-0.01 (-0.83%)
At close: May 13, 2025, 3:59 PM
1.30
8.22%
Pre-market: May 14, 2025, 08:25 AM EDT
-0.83% (1D)
| Bid | 1.22 |
| Market Cap | 85.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -135.12M |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -0.61 |
| Forward PE | -0.67 |
| Analyst | Buy |
| Ask | 1.31 |
| Volume | 791,102 |
| Avg. Volume (20D) | 1,017,058 |
| Open | 1.22 |
| Previous Close | 1.21 |
| Day's Range | 1.18 - 1.24 |
| 52-Week Range | 0.78 - 5.66 |
| Beta | 0.73 |
About VTYX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VTYX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VTYX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+6.96%
Ventyx Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
-22.71%
Ventyx Biosciences shares are trading lower after the company announced its Phase 2 trial of VTX958 for Crohn's disease did not meet its primary endpoint.
